Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas
Diabetes & Metabolism (2017) Vol. 43, pp. 2S20-2S27
Closed Access | Times Cited: 85

Showing 26-50 of 85 citing articles:

Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release
Yakun Li, Bingyang Xu, Jun Yang, et al.
Pharmacological Research (2021) Vol. 173, pp. 105867-105867
Closed Access | Times Cited: 26
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
Luis M. Pérez‐Belmonte, Jaime Sanz‐Cánovas, María Dolores García de Lucas, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 17
Update on the management of diabetes in long-term care facilities
Thaer Idrees, Iris A. Castro-Revoredo, Alexandra L. Migdal, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 4, pp. e002705-e002705
Open Access | Times Cited: 17
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C. Bain, Heidrun Bosch‐Traberg, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus
Toru Suzuki, Tatsuya Sato, Marenao Tanaka, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 7, pp. 108779-108779
Open Access | Times Cited: 3
Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale, Jonida Haxhi, Tiziana Cirrito, et al.
Current Opinion in Pharmacology (2020) Vol. 54, pp. 91-101
Closed Access | Times Cited: 26
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Kevan C. Herold, Jesse Reynolds, James Dziura, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 11, pp. 2045-2054
Open Access | Times Cited: 24
Effect of glucagon‐like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Daniel Yuan, Harman Sharma, Anirudh Krishnan, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 9, pp. 1869-1881
Open Access | Times Cited: 15
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Wei Huang, Yiyuan Chen, Ziqi Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10882-10882
Open Access | Times Cited: 14
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
Francesco Giorgino, Irene Caruso, Julia Moellmann, et al.
Metabolism (2019) Vol. 104, pp. 154045-154045
Closed Access | Times Cited: 24
Chronic kidney disease as a cardiovascular risk factor
Rafael Carmena, Juan F. Ascaso, Josep Redón
Journal of Hypertension (2020) Vol. 38, Iss. 11, pp. 2110-2121
Closed Access | Times Cited: 23
Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases
Natalie Youssef, Mohamed Noureldein, Rachel Njeim, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1360-1360
Open Access | Times Cited: 18
Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations
José Luis Górriz, Irene Romera, Amelia Cobo, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 389-421
Open Access | Times Cited: 13
Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
Qian Zhao, Jiale Dong, Han Liu, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 1283-1301
Open Access | Times Cited: 7
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
David León Jiménez, David Z.I. Cherney, Petter Bjornstad, et al.
AJP Renal Physiology (2018) Vol. 315, Iss. 5, pp. F1406-F1415
Open Access | Times Cited: 23
Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS
Edgar D. Torres Fernandez, Alexandra M. Huffman, Maryam Syed, et al.
Endocrinology (2019) Vol. 160, Iss. 12, pp. 2787-2799
Open Access | Times Cited: 22
Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells
Yao Wang, Wei He, Wei Wei, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 17
Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Tomislav Bulum
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2586-2586
Open Access | Times Cited: 12
Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN)
Jie Liu, Shanshan Guo, Hui Li, et al.
Pakistan Journal of Medical Sciences (2022) Vol. 38, Iss. 5
Open Access | Times Cited: 11
Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
José C. De La Flor, Javier Deira Lorenzo, Alexander Marschall, et al.
Case Reports in Nephrology and Dialysis (2022) Vol. 12, Iss. 3, pp. 238-247
Open Access | Times Cited: 11
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Kevin Yau, Ayodele Odutayo, Satya Dash, et al.
Canadian Journal of Cardiology (2023) Vol. 39, Iss. 12, pp. 1816-1838
Closed Access | Times Cited: 6
Renal outcomes with dipeptidyl peptidase-4 inhibitors
André Scheen, Pierre Delanaye
Diabetes & Metabolism (2017) Vol. 44, Iss. 2, pp. 101-111
Closed Access | Times Cited: 21
Liraglutide reduces hepatic glucolipotoxicity‑induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats
Jun Guo, Li Cai, Chunxiao Yang, et al.
Molecular Medicine Reports (2018)
Open Access | Times Cited: 20
Effects of incretin-based therapies on renal function
Vasilis Tsimihodimos, Moses Elisaf
European Journal of Pharmacology (2017) Vol. 818, pp. 103-109
Closed Access | Times Cited: 19
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats
Rania G. Abdel‐latif, Amira F. Ahmed, Gehan H. Heeba
Life Sciences (2020) Vol. 263, pp. 118592-118592
Closed Access | Times Cited: 17

Scroll to top